An Aβ sequestration approach using non-antibody Aβ binding agents

Current Alzheimer Research

Volumn 2, Issue 2, 2005, Pages 265-268

  Matsuoka, Yasuji ^a   Shao, Li ^b   Debnath, Manik ^b   Lafrancois, John ^c   Becker, Araanda ^a   Gray, Audrey ^a   Aisen, Paul ^a   Mathis, Chester ^b   Klunk, William ^b   Duff, Karen ^c  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA BINDING AGENT; AMYLOID BETA PROTEIN; CONGO RED; NOOTROPIC AGENT; UNCLASSIFIED DRUG; DRUG DERIVATIVE; MEMBRANE PROTEIN; PRESENILIN 1;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; BINDING AFFINITY; CONFERENCE PAPER; HUMAN; IMMUNOMODULATION; MICROGLIA; PHAGOCYTOSIS; PRIORITY JOURNAL; ANIMAL; ARTICLE; COMPARATIVE STUDY; GENETICS; METABOLISM; MOUSE; PHYSIOLOGY; PROTEIN BINDING; TRANSGENIC MOUSE;

AMYLOID BETA-PROTEIN; ANIMALS; CONGO RED; MEMBRANE PROTEINS; MICE; MICE, TRANSGENIC; PRESENILIN-1; PROTEIN BINDING;

EID: 20844459139     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/1567205053585774     Document Type: Conference Paper

References (17)

1. Selkoe DJ. Physiological production of the beta-amyloid protein and the mechanism of Alzheimer's disease. Trends Neurosci 16: 403-409 (1993).
2. Hewlett DR, Simmons DL, Dingwall C, and Christie G. In search of an enzyme: the beta-secretase of Alzheimer's disease is an aspartic proteinase. Trends Neurosci 23: 565-570 (2000).
3. Lemere CA, Spooner ET, LaFrancois J, Malester B, Mori C, Leverone JF, et al. Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. Neurobiol Dis 14: 10-18 (2003).
4. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, and Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98: 8850-8855 (2001).
5. Matsuoka Y, Saito M, LaFrancois J, Saito M, Gaynor K, Olm V, et al. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci 23: 29-33 (2003).
6. Das P, Howard V, Loosbrock N, Dickson D, Murphy MP, and Golde TE. Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. J Neurosci 23: 8532-8538 (2003).
7. Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D, et al. Non-Fc-Mediated Mechanisms Are Involved in Clearance of Amyloid-beta In Vivo by Immunotherapy. J Neurosci 22: 7873-7878 (2002).
8. Wilcock DM, Munireddy SK, Rosenthal A, Ugen KE, Gordon MN, and Morgan D. Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol Dis 15: 11-20 (2004).
9. Bergamaschini L, Rossi E, Storini C, Pizzimenti S, Distaso M, Perego C, et al. Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaques and beta-amyloid accumulation in a mouse model of Alzheimer's disease. J Neurosci 24: 4181-4186 (2004).
10. Isaacs AM, Yuan M, Yankner BA. Transthyretin expression in the aging brain and modulation of Abeta deposition. 9th International Conference on Alzheimer's Disease and Related Disorders, P4-351 (2004).
11. Deane R, Du YS, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9: 907-913 (2003).
12. Klunk WE, Bacskai BJ, Mathis CA, Kajdasz ST, McLellan ME, Frosch MP, et al. Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol 61: 797-805 (2002).
13. Mathis CA, Wang Y, and Klunk WE. Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain. Curr Pharm Des 10: 1469-1492 (2004).
14. Styren SD, Hamilton RL, Styren GC, and Klunk WE. X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer's disease pathology. J Histochem Cytochem 48: 1223-1232 (2000).
15. Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 4: 97-100 (1998).
16. Horikoshi Y, Sakaguchi G, Becker AG, Gray AJ, Duff K, Aisen PS, et al. Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant. Biochem Biophys Res Commun 319: 733-737 (2004).
17. Matsubara E, Frangione B, and Ghiso J. Characterization of apolipoprotein J-Alzheimer's A beta interaction. J Biol Chem 270: 7563-7567 (1995).